ValiRx plc Share Price

VAL

GB00BLH13C52

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 01:04:20 10/07/2026 pm IST			5-day change	1st Jan Change
0.1495 ^GBX	-0.33%		-6.56%	-55.37%

23/06	EARNINGS AND TRADING: ValiRx profit slides; Ukrproduct loss narrows	AN
22/06	Maintel fundraising completes; ValiRx ends deal	AN

ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/26/10	GBX 0.1495	-0.33%	4,73,943
09/26/09	GBX 0.1500	-3.23%	1,96,00,569
08/26/08	GBX 0.1550	0.00%	2,265
07/26/07	GBX 0.1550	0.00%	4,602
06/26/06	GBX 0.1550	-3.13%	31,54,434

Delayed Quote London S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	24.88L 33.33L 29.16L 26.89L 47.23L 32Cr 48.01L 3.22Cr 1.26Cr 16Cr 1.25Cr 1.22Cr 54Cr	P/E 2023	-2.94x	P/E 2024	-0.53x
Enterprise Value	9L 12.65L 11.06L 10.2L 17.92L 12Cr 18.22L 1.22Cr 47.9L 5.93Cr 47.48L 46.45L 21Cr	EV / Sales 2023	61,29,41,875x	EV / Sales 2024	2,72,64,249x
Free-Float	93.4%	Yield 2023 *	-	Yield 2024	-

23/06	EARNINGS AND TRADING: ValiRx profit slides; Ukrproduct loss narrows	AN
22/06	Maintel fundraising completes; ValiRx ends deal	AN
22/06	Valirx plc Announces the Resignation of Tralau-Stewart as Chair of the Advisory Board	CI
22/06	ValiRx plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
22/06	Earnings Flash (VAL.L) ValiRx Plc Reports FY25 Revenue GBP31,372	MT
02/06	ValiRx Completes Oncology Assets Evaluation Deal with Stingray Bio	MT
28/05	ValiRx subsidiary Cytolytix granted "core" European patent	AN
27/05	ValiRx Unit Wins European Patent for Anti-Cancer Peptide Patent	MT
21/05	ValiRx Raises Funds via Retail Offering	MT
18/05	ValiRx to Raise Funds via Retail Offer	MT
15/05	IAG launches new buyback; Forgent settles legal case	AN
15/05	WINNERS & LOSERS: Kendrick drilling results; Blackbird new approach	AN
15/05	ValiRx Seeks to Raise Over GBP1 Million via Share Issue	MT

24/25/24	ValiRx PLC - Director Disclosure Update	AQ
19/24/19	ValiRx plc - Inaphaea Evaluation and Commercial Use Agreement	AQ
06/23/06	ValiRx strikes deal with Ambrose Healthcare to license late-stage cancer treatment	AQ
01/23/01	ValiRx signals launch of new strategy with Nottingham laboratories	AQ
16/22/16	ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment	AQ

1 day	-0.33%
1 week	-6.56%
Current month	-6.56%
1 month	-16.94%
3 months	-51.77%
6 months	-59.04%
Current year	-55.37%

1 week	0.14	0.17
1 month	0.14	0.19
Current year	0.14	0.48
1 year	0.14	0.85
3 years	0.14	15
5 years	0.14	65
10 years	0.14	1,436.25

ValiRx plc Share Price

Stocks

VAL

GB00BLH13C52

Biotechnology & Medical Research

Valuation: ValiRx plc

Chart: ValiRx plc

Latest news : ValiRx plc

Press Releases: ValiRx plc

Quotes and Performance

Course Extremes

Managers and Directors: ValiRx plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Manager	Title	Age	Since
Mark Eccleston CEO	Chief Executive Officer	55	12/08/2024
Gerald Desler DFI	Director of Finance/CFO	81	-
Michelle Barnard CTO	Chief Tech/Sci/R&D Officer	-	27/03/2025

Director	Title	Age	Since
Gerald Desler BRD	Director/Board Member	81	01/09/2006
Martin Gouldstone CHM	Chairman	59	25/07/2024
Mark Eccleston BRD	Director/Board Member	55	12/08/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
04/03	Mark Eccleston	Buy	Chief Executive Officer	10,00,000	0.1346%
18/22/18	Stella Panu	Free	Director	75,000	0.0832%
18/22/18	Stella Panu	Free	Director	75,000	0.0832%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALIRX PLC	-0.33%	-6.56%	-72.82%	-97.94%	15.43L
ARGENX SE	+0.03%	-4.07%	+64.19%	+126.68%	5.7TCr
WUXI APPTEC CO., LTD.	+4.91%	-0.19%	+73.70%	+92.14%	5.36TCr
INSMED INCORPORATED	+1.48%	+5.97%	+22.59%	+495.47%	2.56TCr
BIONTECH SE	-0.59%	-4.68%	-16.82%	-12.99%	2.35TCr
WUXI BIOLOGICS (CAYMAN) INC.	+2.21%	+0.80%	+47.32%	-0.37%	1.94TCr
GENMAB A/S	-0.38%	+2.73%	+37.65%	-24.87%	1.81TCr
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+203.03%	+348.11%	1.65TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.89%	+3.01%	+53.07%	-	1.41TCr
EXELIXIS, INC.	+1.76%	+2.24%	+29.57%	+195.70%	1.44TCr
Average	+1.04%	-0.43%	+44.15%	+124.66%	2.42TCr
Weighted average by Cap.	+1.46%	-0.31%	+57.42%	+143.07%

	2023	2024
Net sales	0.01 0.01 0.01 0.01 0.02 1.23 0.02 0.12 0.05 0.6 0.05 0.05 2.09	0.05 0.07 0.06 0.05 0.09 6.37 0.1 0.64 0.25 3.13 0.25 0.24 10.83
Net income	-20.38L -27.3L -23.88L -22.02L -38.68L -26Cr -39.32L -2.64Cr -1.03Cr -13Cr -1.02Cr -1Cr -44Cr	-19.16L -25.67L -22.45L -20.7L -36.36L -24Cr -36.97L -2.48Cr -97.2L -12Cr -96.35L -94.27L -42Cr
Net Debt	-2L -2L -2L -2L -3L -1.95Cr -3L -19.75L -8L -95.84L -8L -8L -3.32Cr	-15.44L -20.69L -18.1L -16.69L -29.31L -20Cr -29.8L -2Cr -78.35L -9.7Cr -77.66L -75.98L -34Cr